|

MYeloma Resistance And Clonal Evolution

RECRUITINGSponsored by Nantes University Hospital
Actively Recruiting
SponsorNantes University Hospital
Started2019-02-11
Est. completion2034-02-11
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03807128

Summary

Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014)
* Patient having consented to participate in the study and his/her biocollection
* Patient affiliated to or benefiting from a social security scheme or similar

Exclusion Criteria:

* Minors
* Major under guardianship or curatorship
* Protected persons.
* Pregnant or breast-feeding women
* Persons benefiting from the AME

Conditions2

CancerMultiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.